Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

COSCIENS Biopharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(113)
•••
Post by prophetoffactzon Jul 12, 2024 8:34am
90 Views
Post# 36129824

Strategic acquisitions

Strategic acquisitionsGilles, "constantly looking for strategic growth opportunities.” June 2024

Perplexity Ai on potential strategic acquisitions:

Some strategic acquisitions Ceapro could make after the merger to expand its wound healing product portfolio:
  1. Acquire companies with novel wound dressings or topical formulations that could incorporate Ceapro's oat-derived beta glucan and avenanthramides. This could accelerate development and commercialization of advanced wound care products.
  2. Partner with or acquire companies developing biologics or cell therapies for wound healing. Combining Ceapro's delivery technologies with regenerative medicine approaches could create unique combination products.
  3. Expand into veterinary wound care by acquiring companies with pet-safe wound healing products. 
  4. Acquire companies with complementary technologies that enhance the delivery and efficacy of Ceapro's wound healing ingredients, such as sustained-release platforms or penetration enhancers.
  5. Expand geographically by acquiring regional wound care companies to gain market access in new territories and accelerate global commercialization of Ceapro's wound healing product pipeline.
The merger provides Ceapro with a stronger balance sheet and access to Aeterna's pharmaceutical development expertise to advance its wound healing product pipeline. Strategic acquisitions aligned with Ceapro's core oat-based active ingredients could drive growth in the large and expanding wound care market.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities